

AMENDMENTS TO THE CLAIMS:

Please cancel claims 21-25, 26, 27, 29, 31, 34 and 36-38 without prejudice.

Please add new claims 39-42.

Please amend claims 20, 28, 30, 32, 33 and 35 as follows:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-19 (Cancelled)

20. (Currently amended) A method for diagnosing colon cancer comprising detecting evidence of differential expression of PPP3CC in a patient colon sample ~~wherein evidence of differential expression indicates that the patient has cancer, wherein evidence of differential expression is detected by measuring the level of an expression product of PPP3CC; said expression product at least 98% identical to SEQ ID NO:1587; wherein an increase in the level of the expression product in the sample of at least 50% relative to a non-cancerous control is indicative of colon cancer.~~

Claims 21-27 (Cancelled)

28. (Currently amended) The method of claim 20 ~~25~~ wherein the expression product is a mRNA having a sequence of SEQ ID NO:1587.

Claim 29 (Cancelled)

30. (Currently amended) The method of claim 20 ~~29~~ wherein the control is a known normal tissue of the same tissue type as in the patient sample.

Claim 31 (Cancelled)

32. (Currently amended) The method of claim 20 29 wherein the level of the expression product in the sample is increased at least 100% relative to the control.

33. (Currently amended) The method of claim 20 29 wherein the level of the expression product in the sample is increased at least 150% relative to the control.

Claim 34 (Cancelled)

35. (Currently amended) A method of diagnosing cancer comprising:
a) determining the level of an expression product comprising a nucleotide sequence ~~having at least 95% sequence identity to a sequence~~ of SEQ ID NO:1587, or a full complement thereof, in a patient sample; and
b) comparing said level of the expression product in (a) to a level of the expression product in a second sample, said second sample comprising a normal tissue, wherein a difference between the level of the expression products in (a) and the level of the expression products in the second sample indicates that the patient has lymphoma, colon cancer, stomach cancer or breast cancer.

Claims 36-38 (Cancelled)

39. (New) A method for diagnosing carcinoma, lymphoma, prostate cancer, stomach cancer and breast cancer comprising detecting evidence of differential expression of PPP3CC in a patient sample, wherein evidence of differential expression is detected by measuring the level of an expression product of PPP3CC, said expression product at least 98% identical to SEQ ID NO:1587, wherein an increase in the level of the expression product in the sample of at least 50% relative to a control is indicative of carcinoma, lymphoma, prostate cancer, stomach cancer or breast cancer, wherein the control is a known sample comprising normal tissue of the same tissue type as in the patient sample.

40. (New) The method of claim 39 wherein the level of the expression product in the sample is increased at least 100% relative to the control.

41. (New) The method of claim 39 wherein the level of the expression product in the sample is increased at least 150% relative to the control.

42. (New) The method of either claim 20 or claim 39 wherein the expression product at least 98% identical to SEQ ID NO:1587 has the same expression profile as SEQ ID NO:1587.